TITLE

Medical Therapy for Asthma: Updates from the NAEPP Guidelines

AUTHOR(S)
ELWARD, KURTIS S.; POLLART, SUSAN M.
PUB. DATE
November 2010
SOURCE
American Family Physician;11/15/2010, Vol. 82 Issue 10, p1242
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Proper care of patients with asthma involves the triad of systematic chronic care plans, self-management support, and appropriate medical therapy. Controller medications (inhaled corticosteroids, long-acting beta2 agonists, and leukotriene receptor antagonists) are the foundation of care for persistent asthma and should be taken daily on a long-term basis to achieve and maintain control of symptoms. Inhaled corticosteroids are the preferred controller medication; studies have demonstrated that when inhaled corticosteroids are used consistently, they improve asthma control more effectively than any other single long-term control medication. Combining long-acting beta2 agonists and inhaled corticosteroids is effective and safe when inhaled corticosteroids alone are insufficient, and such combinations are an alternative to increasing the dosage of inhaled corticosteroids. For patients with mild persistent asthma, leukotriene receptor antagonists are an alternative, second-line treatment option. They are easy to use, have high rates of compliance, and can provide good symptom control in many patients. Leukotriene receptor antagonists can also be used as an adjunctive therapy with inhaled corticosteroids, but for persons 12 years and older the addition of long-acting beta2 agonists is preferred. Inhaled short-acting beta2 agonists are the most effective therapy for rapid reversal of airflow obstruction and prompt relief of asthmatic symptoms. Increasing the use of short-acting beta2 agonists or using them more than two days per week or more than two nights per month generally indicates inadequate control of asthma and the need to initiate or intensify anti-inflammatory therapy. Oral systemic corticosteroids should be used to treat moderate to severe asthma exacerbations.
ACCESSION #
55418905

 

Related Articles

  • Cysteinyl Leukotriene Receptor Antagonists and Thromboxane Synthase Inhibitors: New Targets to Treat Asthma. Lima, L�dia M.; Fraga, Carlos Alberto M.; Barreiro, Eliezer J. // Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy A;Mar2004, Vol. 3 Issue 1, p9 

    Cysteinyl leukotrienes (LTC 4 , LTD4 and LTE4 ) and thromboxane A2 are important metabolites of arachidonic acid cascate involved in a variety of cellular functions and diseases. These eicosanoids have been implicated as key mediators in the development and progression of bronchial asthma....

  • Inhaled corticosteroids and skin atrophy.  // WHO Drug Information;2004, Vol. 18 Issue 3, p213 

    The article reports that inhaled corticosteroids can cause skin atrophy. This adverse effect may be exacerbated by sun exposure, possibly via a cumulative mechanism. Inhaled corticosteroids have an essential role in the management of asthma. Inhalation allows high concentrations of...

  • Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Hauber, A. Brett; Mohamed, Ateesha F.; Johnson, F. Reed; Meddis, David; Wagner, Samuel; O'Dowd, Liza // Allergy & Asthma Proceedings;Mar/Apr2009, Vol. 30 Issue 2, p139 

    The Onset-of-Effect Questionnaire (OEQ) is a self-administered instrument used to assess patient perception of how quickly asthma maintenance medications begin to work. This study was designed to quantify the relative importance that patients using combination inhaled corticosteroid and...

  • Step-Down Therapy for Controlled Mild Persistent Asthma.  // Travel Medicine Advisor;Aug2007, Vol. 17 Issue 8, p16 

    The article discusses a study on the suggested treatment for persistent asthma. Low-dose inhaled corticosteroids (LDIC) is used as an initial maintenance therapy and is used as a step-down therapy in reducing the use of pharmacotherapy without increasing asthma symptomatology. It is recommended...

  • Identifying general practice patients diagnosed with asthma and their exacerbation episodes from prescribing data. Pont, Lisa G.; van der Werf, G. Th.; Denig, P.; Haaijer-Ruskamp, F. // European Journal of Clinical Pharmacology;Jan2002, Vol. 57 Issue 11, p819 

    Objective: To determine the reliability of identifying patients diagnosed with asthma in general practice and their asthma exacerbation episodes from prescribing data. Data source: Automated database from 17 general practitioners (29,805 patients) in the northern Netherlands. Study design:...

  • Blocking leukotrienes optimize asthma control: The BLOC survey. Idrees, Majdy M.; Al Moamary, Mohamed S. // Annals of Thoracic Medicine;Jul-Sep2007, Vol. 2 Issue 3, p99 

    Objective: The aim of this study was to evaluate asthma control after the introduction of a leukotriene modifier (Montelukast), in addition to the current controller asthma therapies, in patients with inadequately controlled mild-to-moderate persistent asthma. Asthma control and patient...

  • Antileukotrienes as Adjunctive Therapy in Acute Asthma. Kuitert, Lieske M. E.; Watson, Danie // Drugs;2007, Vol. 67 Issue 12, p1665 

    The leukotriene receptor antagonists (LTRAs) are a comparatively new class of asthma drugs that exhibit both bronchodilator and anti-inflammatory properties. There is a substantial body of evidence for their benefit in the management of chronic asthma in both adults and children, and...

  • Pharmacotherapy -- first-line maintenance therapy.  // CMAJ: Canadian Medical Association Journal;9/13/2005 Supplement, Vol. 173, pS28 

    The article discusses the recommended therapeutics in treating long-term asthma in children which include inhaled corticosteroids and leukotriene receptor anatgonists that are used in first-line maintenance therapy. It provides a literature review that would support the safety and efficacy of...

  • In patients with stable persistent asthma, can lower doses of inhaled corticosteroid medication control symptoms and maintain optimal pulmonary function as well as high doses? Jackson, Eric A. // Journal of Family Practice;Jun2000, Vol. 49 Issue 6, p494 

    This article discusses research being done on the effectiveness of low-dose budesonide in long-term asthma control, with reference to a study by A. Foresi, M. C. Morellu and E. Catena, which appeared in the 2000 issue of the "Chest." Patients included in this study have perennial asthma and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics